The Spectrum of Neurological and Sensory Abnormalities in Gaucher Disease Patients: A Multidisciplinary Study (SENOPRO)
- PMID: 37240189
- PMCID: PMC10218502
- DOI: 10.3390/ijms24108844
The Spectrum of Neurological and Sensory Abnormalities in Gaucher Disease Patients: A Multidisciplinary Study (SENOPRO)
Abstract
Gaucher disease (GD) has been increasingly recognized as a continuum of phenotypes with variable neurological and sensory involvement. No study has yet specifically explored the spectrum of neuropsychiatric and sensory abnormalities in GD patients through a multidisciplinary approach. Abnormalities involving the nervous system, including sensory abnormalities, cognitive disturbances, and psychiatric comorbidities, have been identified in GD1 and GD3 patients. In this prospective study, named SENOPRO, we performed neurological, neuroradiological, neuropsychological, ophthalmological, and hearing assessments in 22 GD patients: 19 GD1 and 3 GD3. First, we highlighted a high rate of parkinsonian motor and non-motor symptoms (including high rates of excessive daytime sleepiness), especially in GD1 patients harboring severe glucocerebrosidase variants. Secondly, neuropsychological evaluations revealed a high prevalence of cognitive impairment and psychiatric disturbances, both in patients initially classified as GD1 and GD3. Thirdly, hippocampal brain volume reduction was associated with impaired short- and long-term performance in an episodic memory test. Fourthly, audiometric assessment showed an impaired speech perception in noise in the majority of patients, indicative of an impaired central processing of hearing, associated with high rates of slight hearing loss both in GD1 and GD3 patients. Finally, relevant structural and functional abnormalities along the visual system were found both in GD1 and GD3 patients by means of visual evoked potentials and optical coherence tomography. Overall, our findings support the concept of GD as a spectrum of disease subtypes, and support the importance of in-depth periodic monitoring of cognitive and motor performances, mood, sleep patterns, and sensory abnormalities in all patients with GD, independently from the patient's initial classification.
Keywords: Gaucher disease; Parkinson’s disease; audiometric; cognitive; evoked potentials; hearing loss; psychiatric; sleep.
Conflict of interest statement
FG declares funding, having served on advisory boards for/received honoraria for lecturing or moderating meetings from Sanofi, Novartis, and Takeda in the last 3 years. The remaining authors declare no competing conflicts of interest.
Similar articles
-
Novel hyperkinetic dystonia-like manifestation and neurological disease course of Swedish Gaucher patients.Blood Cells Mol Dis. 2018 Feb;68:86-92. doi: 10.1016/j.bcmd.2016.10.011. Epub 2016 Oct 21. Blood Cells Mol Dis. 2018. PMID: 27789132
-
Gaucher disease: clinical phenotypes and refining GBA mutational spectrum in Thai patients.Orphanet J Rare Dis. 2021 Dec 20;16(1):519. doi: 10.1186/s13023-021-02151-2. Orphanet J Rare Dis. 2021. PMID: 34930372 Free PMC article.
-
Evaluation of the frequency of non-motor symptoms of Parkinson's disease in adult patients with Gaucher disease type 1.Orphanet J Rare Dis. 2019 May 10;14(1):103. doi: 10.1186/s13023-019-1079-4. Orphanet J Rare Dis. 2019. PMID: 31077260 Free PMC article.
-
Neuropathological Features of Gaucher Disease and Gaucher Disease with Parkinsonism.Int J Mol Sci. 2022 May 23;23(10):5842. doi: 10.3390/ijms23105842. Int J Mol Sci. 2022. PMID: 35628652 Free PMC article. Review.
-
Gaucher disease and its treatment options.Ann Pharmacother. 2013 Sep;47(9):1182-93. doi: 10.1177/1060028013500469. Ann Pharmacother. 2013. PMID: 24259734 Review.
Cited by
-
Fucosidosis: A Review of a Rare Disease.Int J Mol Sci. 2025 Jan 3;26(1):353. doi: 10.3390/ijms26010353. Int J Mol Sci. 2025. PMID: 39796208 Free PMC article. Review.
-
Recent Advances in Visual Dysfunction and Ocular Biomarkers in Neurological Disorders.Eye Brain. 2025 Jun 14;17:49-67. doi: 10.2147/EB.S516393. eCollection 2025. Eye Brain. 2025. PMID: 40534708 Free PMC article. Review.
-
A review of type 3 Gaucher disease: unique neurological manifestations and advances in treatment.Acta Neurol Belg. 2024 Aug;124(4):1213-1223. doi: 10.1007/s13760-024-02493-1. Epub 2024 Feb 28. Acta Neurol Belg. 2024. PMID: 38413480 Review.
-
Examining the Role of a Functional Deficiency of Iron in Lysosomal Storage Disorders with Translational Relevance to Alzheimer's Disease.Cells. 2023 Nov 16;12(22):2641. doi: 10.3390/cells12222641. Cells. 2023. PMID: 37998376 Free PMC article. Review.
-
Gaucher Disease Coexisting with Cytomegalovirus Infection: A Rare Presentation in an Infant.Am J Case Rep. 2024 Mar 21;25:e943398. doi: 10.12659/AJCR.943398. Am J Case Rep. 2024. PMID: 38509666 Free PMC article.
References
-
- Stirnemann J., Belmatoug N., Camou F., Serratrice C., Froissart R., Caillaud C., Levade T., Astudillo L., Serratrice J., Brassier A., et al. A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments. Int. J. Mol. Sci. 2017;18:441. doi: 10.3390/ijms18020441. - DOI - PMC - PubMed
-
- Pastores H. Gaucher Disease. University of Washington; Seattle, WA, USA: 2018. GeneReviews®. - PubMed
-
- Martins A.M., Valadares E.R., Porta G., Coelho J., Filho J.S., Dudeque Pianovski M.A., Kerstenetzky M.S., de Fátima Pombo Montoril M., Aranda P.C., Pires R.F., et al. Recommendations on Diagnosis, Treatment, and Monitoring for Gaucher Disease. J. Pediatr. 2009;155:S10–S18. doi: 10.1016/j.jpeds.2009.07.004. - DOI - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical